- Panorama is the second Phase 3 trial of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...
About 1 in 4 people suffer from an anxiety disorder at some point in their lives. These include panic disorder with sudden, severe anxiety attacks; generalized anxiety disorder, in which sufferers ...
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
- Recently announced positive Phase 1 topline safety, pharmacokinetic (“PK”) and pharmacodynamic (“PD”) data show that intravenous (“IV”) CYB004 demonstrated robust and rapid-onset psychedelic effects ...
Researchers at the Laureate Institute for Brain Research (LIBR) in Tulsa, Okla., have identified an abnormal link between the autonomic and central nervous systems, specifically via communication ...
CLEVELAND — Researchers narrowed down what appears to be the correct dosage during a first ever rigorous clinical trial examining LSD as a treatment for generalized anxiety disorder, with results ...
A clinical trial’s encouraging results won US Food and Drug Administration breakthrough therapy status for an LSD formulation to treat generalized anxiety disorder, Mind Medicine Inc. announced ...
Cognitive behavioral therapy (CBT) should be considered first-line treatment for generalized anxiety disorder in adults, according to a systematic review and network meta-analysis of 66 randomized ...
In a recent study published in the JAMA Journal, researchers examined the different aspects of screening for anxiety disorders in adults. Study: Screening for Anxiety Disorders in Adults. Image Credit ...
- Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results